ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives.International journal of molecular sciences · 2026Review
- Delivering Degradation: Nanomedicine and Programmable Proximity Platforms for Targeted Protein Degradation.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeResistance to androgen receptor (AR) pathway inhibitors necessitates the development of regimens to improve outcomes in metastatic prostate cancer (mPC). This phase Ib clinical trial evaluated the safety/tolerability and pharmacokinetics of bavdegalutamide, an oral proteolysis-targeting chimera AR degrader, combined with abiraterone in patients with mPC experiencing prostate-specific antigen (PSA) progression on abiraterone. PATIENTS AND
methodsPatients received bavdegalutamide 420 mg, abiraterone ≤1,000 mg, and corticosteroid daily. Assessments included safety [dose-limiting toxicities (DLT); treatment-emergent adverse events (TEAE)], pharmacokinetics, PSA control rate, ≥50% PSA decline (PSA50), and radiographic progression-free survival (rPFS).
resultsForty-five patients were treated; seven had AR ligand-binding domain (LBD) mutations. The median duration of exposure was 35.7 weeks; 13 patients were continuing bavdegalutamide at the data cutoff. No DLTs were observed. There were no clinically significant effects of bavdegalutamide on abiraterone pharmacokinetics. Bavdegalutamide 420 mg daily was selected as the recommended phase II dose. TEAEs were mostly grade 1/2 (82.2%), and 17.8% were grade 3. Dose modifications or discontinuations due to TEAEs occurred in 48.9% and 13.3% of patients, respectively. The most common bavdegalutamide-related TEAEs were fatigue (48.9%) and nausea (46.7%). The PSA control rate was 48.9% [95% confidence interval (CI), 33.7-64.2]. The PSA50 response rate was 24.4% (95% CI, 12.9-39.5), including in five out of seven patients with AR LBD mutations. The median time to PSA progression was 2.8 months (95% CI, 1.5-6.5). The median rPFS was 16.3 months (95% CI, 8.2-not calculable).
conclusionsBavdegalutamide combined with abiraterone demonstrated a manageable safety profile with no major drug-drug interactions and evidence of clinical activity in mPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.